Clinical Trial Matcher

Condition

Amyotrophic Lateral Sclerosis clinical trials

Recruiting and not-yet-recruiting Amyotrophic Lateral Sclerosis studies, refreshed daily. Want them ranked for you? Paste your diagnosis, treatments, and location and the matcher checks ClinicalTrials.gov, EU, WHO, and ISRCTN registries for studies that fit.

Match Amyotrophic Lateral Sclerosis trials to my notes

315 studies matched on ClinicalTrials.gov for the query below. Retrieved November 7, 2026. This page does not say who can enroll.

Query

Amyotrophic Lateral Sclerosis OR Motor Neuron Disease

Names the matcher also recognizes: Amyotrophic Lateral Sclerosis, ALS, Motor Neuron Disease. Abbreviations shorter than five letters stay off the query so a string such as MS does not pull unrelated records. Status filter: recruiting or not yet recruiting. The same names are how a personalized search starts. Washout timing still needs the treatment end date you enter on the search form. Read how matching works before treating any line below as a fit.

Studies in this retrieval

  1. NCT03217396

    Biomarkers of Synaptic Damage in Multiple Sclerosis

    Recruiting · Not specified · registry updated 2022-10-28

    A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.

  2. NCT07322003

    Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

    Recruiting · Phase 3 · registry updated 2026-10-27

    The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests

  3. NCT04885374

    China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine

    Recruiting · Not specified · registry updated 2021-05-13

    A multi-center registration study of clinical characteristics of amyotrophic lateral sclerosis (ALS) patients with traditional Chinese medicine (TCM).

  4. NCT07698496

    Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)

    Not Yet Recruiting · Not Applicable · registry updated 2026-07-13

    Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment. In France, the Association du Locked-In Syndrome (ALIS) reports approximately 500 individuals with LIS, most of whom live at home. The quality of life of people with LIS depends strongly on their ability to communicate, and speech synthesis is the mode of communication restoration most desired by individuals with LIS. Several surveys have shown that improving communication abilities in these individuals leads to a significant improvement in their quality of life as well as that of their caregivers. Natural speech allows the production of an average of 150 words per minute. Non-invasive communication methods, whether based on residual motor function (eye-blink code) or on brain-machine or brain-computer interfaces (Brain-Computer Interface, BCI) using scalp electroencephalographic (EEG) signals, involve a high cognitive load and have low efficiency (spelling only a few letters per minute)....

  5. NCT07737977

    Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients

    Not Yet Recruiting · Not specified · registry updated 2026-07-30

    Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.

  6. NCT06726577

    TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis

    Recruiting · Phase 1, Phase 2 · registry updated 2026-10-02

    This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design. This experiment is divided into two groups: the experimental drug group and the placebo group. Successful participants will be randomly assigned to the two groups, with an expected enrollment of 60 participants. There will be 30 participants in the experimental drug group and 30 participants in the placebo group. During the treatment period, the experimental drug group received intravenous injections of 0.5mL/kg TP04HN106 each time; The placebo group received intravenous injections of 0.5mL/kg of saline each time. During the extension period, all subjects received intravenous injection of 0.5mL/kg TP04HN106. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment. The subjects who were successfully screened in the experiment were enrolled in sequence, and the safety, tolerability, efficacy, and pharmacokinetic characteristics of the experimental drug were evaluated after administration....

  7. NCT06666816

    Observational Study to Observe Variations of Gait Parameters in Patients With Neuromuscular Diseases

    Recruiting · Not specified · registry updated 2026-01-20

    This study has the general objective of observing walking parameters during a clinical test to objectively estimate fatigue in patients with neuromuscular diseases. Furthermore, the investigators want to evaluate the feasibility of collecting physical activity in daily life conditions during a one-week monitoring period using a wearable sensor.

  8. NCT06689982

    Tofacitinib in Patients With Amyotrophic Lateral Sclerosis

    Not Yet Recruiting · Early Phase 1 · registry updated 2024-11-15

    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, of which motor-neuron's degeneration may be associated with neuroinflammation. Tofacitinib is a Janus kinase (JAK) inhibitor that affects cellular hematopoiesis and cellular immune function. At the same time, tofacitinib is suitable for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. This study is a single center, single arm, proof of concept, clinical trial study, and it is planned to use tofacitinib to carry out a clinical trial to observe the treatment effect of ALS patients.